{"preliminary_commentary":{"by_channel":{"x_thread":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["relugolix"]],"indication":"oligometastatic prostate cancer","name":"NRG Promethean","nct_id":"NCT05053152","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nrg-promethean-nct05053152. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive placebo PO QD on days 1-180 and undergo SABR for 1-3 weeks in the absence of disease progression or unacceptable toxicity. Patients may also undergo bone scan, CT, MRI, PSMA PET/CT or PET/MRI, and/or fluciclovine F18 PET/CT or PET/MRI at time of disease progression. Patients may optionally undergo urine and blood sample collection throughout the trial.","label":"Arm I (placebo, SABR)","type":"PLACEBO_COMPARATOR"},{"description":"Patients receive relugolix PO QD on days 1-180 and undergo SABR for 1-3 weeks in the absence of disease progression or unacceptable toxicity. Patients may also undergo bone scan, CT, MRI, PSMA PET/CT or PET/MRI, and/or fluciclovine F18 PET/CT or PET/MRI at time of disease progression. Patients may optionally undergo urine and blood sample collection throughout the trial.","label":"Arm II (relugolix, SABR)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2034-02-01","type":"ESTIMATED"},"conditions":["Oligometastatic Prostate Carcinoma","Prostate Adenocarcinoma","Prostate Ductal Adenocarcinoma","Prostate Intraductal Carcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":{"count":194,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Specimen Collection"],"type":"PROCEDURE"},{"name":"Bone Scan","otherNames":["Bone Scintigraphy"],"type":"PROCEDURE"},{"name":"Computed Tomography","otherNames":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","tomography"],"type":"PROCEDURE"},{"name":"Fluciclovine F18","otherNames":["(18F)Fluciclovine","(18F)GE-148","18F-Fluciclovine","[18F]FACBC","Anti-(18f)FABC","Anti-1-Amino-3-[18F]Fluorocyclobutane-1-Carboxylic Acid","Anti-[18F] FACBC","Axumin","Fluciclovine (18F)","FLUCICLOVINE F-18","GE-148 (18F)","GE-148 F-18"],"type":"OTHER"},{"name":"Magnetic Resonance Imaging","otherNames":["Magnetic Resonance","Magnetic Resonance Imaging (MRI)","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","MRIs","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging","sMRI","Structural MRI"],"type":"PROCEDURE"},{"name":"Placebo Administration","otherNames":[],"type":"DRUG"},{"name":"Positron Emission Tomography","otherNames":["Medical Imaging, Positron Emission Tomography","PET","PET Scan","Positron emission tomography (procedure)","Positron Emission Tomography Scan","Positron-Emission Tomography","PT"],"type":"PROCEDURE"},{"name":"PSMA PET Scan","otherNames":["Prostate-specific Membrane Antigen PET","PSMA PET","PSMA-Positron emission tomography"],"type":"PROCEDURE"},{"name":"Relugolix","otherNames":["N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea","Orgovyx","Relumina","TAK 385","TAK-385","TAK385"],"type":"DRUG"},{"name":"Stereotactic Body Radiation Therapy","otherNames":["SABR","SBRT","Stereotactic Ablative Body Radiation Therapy"],"type":"RADIATION"}],"last_update":"2026-08-17","lead_sponsor":"NRG Oncology","official_title":"A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2029-02-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Radiological progression-free survival (rPFS)","timeFrame":"Time from randomization to the occurrence of radiological progression detected by conventional imaging or death from any cause, assessed up to 5 years"}],"references":[],"start_date":{"date":"2022-04-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study","url":"https://clinicaltrials.gov/study/NCT05053152"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nrg-promethean-nct05053152"}